Overview: Targeted vs General GHRH Stimulation
Tesamorelin and CJC-1295 are both synthetic GHRH analogs that stimulate pituitary GH release, but they have been researched for different primary applications. Tesamorelin is a 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification that has been specifically studied for its effects on visceral adipose tissue (VAT) reduction. CJC-1295 (No DAC) is a 29-amino-acid modified GRF used as a general-purpose GH stimulator, typically stacked with secretagogues. Their different research contexts make them suitable for different protocol objectives in test subjects. For research purposes only.
Head-to-Head Comparison Table
Structure: Tesamorelin = 44 amino acids + hexenoic acid | CJC-1295 = 29 amino acids (modified GRF)
Primary research focus: Tesamorelin = Visceral fat reduction | CJC-1295 = General GH stimulation
Dose: Tesamorelin = 1-2 mg daily | CJC-1295 = 100-300 mcg daily
Frequency: Both = Daily (subcutaneous)
Half-life: Tesamorelin = ~26 minutes | CJC-1295 No DAC = ~30 minutes
Stacking: Tesamorelin = Often used alone | CJC-1295 = Typically stacked with Ipamorelin/GHRP
Vial sizes: Tesamorelin = 10mg | CJC-1295 = 5mg, 10mg
Research stage: Tesamorelin = FDA-approved (for HIV lipodystrophy) | CJC-1295 = Research compound
Cost: Tesamorelin = Higher (larger doses) | CJC-1295 = Lower
Which to Choose for Research
Choose tesamorelin when: The research specifically investigates visceral adipose tissue reduction, the protocol requires a GHRH analog with clinical approval data, or the study examines body composition changes focused on trunk fat in test subjects.
Choose CJC-1295 when: General GH axis stimulation is the objective, the protocol involves stacking with secretagogues (Ipamorelin, GHRP-2/6), or cost-effectiveness is a factor (lower doses required) for research in test subjects.
Tesamorelin's unique research value lies in its demonstrated specificity for visceral fat reduction — an effect not consistently shown with other GHRH analogs. CJC-1295 remains the standard choice for general GH research protocols. For research purposes only.